The company focuses on the discovery and development of proprietary therapeutics, called Toleragens, which target and suppress the production of specific disease-causing antibodies without affecting the protective functions of the immune system.

a biopharmaceutical company, engages in the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets.

It offers PBT-2, which is in Phase II a clinical trial, for patients with Alzheimer’s disease.

The company focuses on the target delivery of chemotherapy drugs for the treatment of cancer.

engages in the development, production, and commercialization of therapeutic proteins through transgenic animal technology